X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Aubagio-Generic (teriflunomide) is an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase. It is indicated for the treatment of patients with relapsing remitting multiple sclerosis.
Lead Product(s): Teriflunomide
Therapeutic Area: Neurology Product Name: pms-Teriflunomide
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Myinfla
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Myinfla
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Montreal Heart Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2021
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Montreal Heart Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2021
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Montreal Heart Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2020
Details:
The first of these sub analyses simultaneously published in the European Heart Journal reveals that early initiation of low-dose colchicine within the first 3 days after MI significantly reduces the risk of ischemic CV events by 48% as vs placebo on top of standard of care.
Lead Product(s): Colchicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Montreal Heart Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.
Lead Product(s): Colchicine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Montreal Heart Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
